Expressions of MAGE-A10 and MAGE-A11 in Breast Cancers and Their Prognostic Significance: a Retrospective Clinical Study

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2011 Dec 27

PMID 22198676

Citations 26

Authors

Yishui Lian

Meixiang Sang

Chunyan Ding

Xinliang Zhou

Xiaojie Fan

Yingying Xu

Weihua Lu

Baoen Shan

Affiliations

Soon will be listed here.

Abstract

Purpose: Melanoma-associated antigens-A (MAGE-A) family is a group of well-characterized cancer/testis antigens (CTA), because they are strictly tumor specific and are shared by many kinds of tumors. However, the expression pattern of MAGE-A10 and MAGE-A11 in breast cancer patients is still unclear. The purpose of our study is to investigate the expression pattern and prognostic significance of MAGE-A10 and MAGE-A11 in breast cancer patients.

Methods: Formalin-fixed and paraffin-embedded tissues and the clinicopathological parameters from 75 primary breast cancer patients were collected. The expressions of MAGE-A10 and MAGE-A11 proteins were immunohistochemically detected, and the association of MAGE-A10 and MAGE-A11 expressions with the clinicopathological parameters and the survival of breast cancer patients were analyzed.

Results: The expression rates of MAGE-A10 and MAGE-A11 in breast cancer specimens were 73.3 and 52.0%, respectively. MAGE-A11 expression was more frequent in estrogen-receptor (ER)-positive breast carcinomas compared with ER-negative breast carcinomas (P = 0.004). MAGE-A11 expression was positively associated with HER-2 expression (P = 0.003). Overall survival of patients with MAGE-A11-negative expression was significantly longer than those patients with positive MAGE-A11 expression (P = 0.030), but no difference of overall survival was found between patients with MAGE-A10-negative and -positive expression (P = 0.881).

Conclusions: MAGE-A10 and MAGE-A11 are tumor-specific antigens, and MAGE-A11 expression probably is a potential poor prognostic factor for breast cancer patients.

Citing Articles

Magea13 attenuates myocardial injury in acute myocardial infarction by inhibiting the cAMP-PKA signaling pathway.

Zheng J, Xu X, Zhang Z, Ge K, Xiang Y, Dai H Apoptosis. 2025; .

PMID: 40056358 DOI: 10.1007/s10495-025-02078-0.

Integrated analysis of single-cell and bulk RNA-sequencing reveals a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in gastric cancer.

Sun J, Kong C, Ye Y, Wang Q, Qu X, Jia L Sci Rep. 2024; 14(1):7648.

PMID: 38561388 PMC: 10985121. DOI: 10.1038/s41598-024-57714-7.

Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer.

Mohsenzadegan M, Razmi M, Vafaei S, Abolhasani M, Madjd Z, Saeednejad Zanjani L Sci Rep. 2022; 12(1):599.

PMID: 35022469 PMC: 8755713. DOI: 10.1038/s41598-021-04510-2.

Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness.

Oh C, Kim H, Oh S, Ko J, Kim Y, Kang K Cancers (Basel). 2021; 13(13).

PMID: 34202157 PMC: 8268034. DOI: 10.3390/cancers13133176.

Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases.

Yang S, Huang X, Lin W, Min J, Miller D, Mayasundari A Nat Commun. 2020; 11(1):4931.

PMID: 33004795 PMC: 7529893. DOI: 10.1038/s41467-020-18708-x.

References

Sang M, Lian Y, Zhou X, Shan B . MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011; 29(47):8496-500. DOI: 10.1016/j.vaccine.2011.09.014. View

De Plaen E, Arden K, Traversari C, Gaforio J, Szikora J, De Smet C . Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994; 40(5):360-9. DOI: 10.1007/BF01246677. View

Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F . Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995; 63(3):375-80. DOI: 10.1002/ijc.2910630313. View

Polyak K . Breast cancer: origins and evolution. J Clin Invest. 2007; 117(11):3155-63. PMC: 2045618. DOI: 10.1172/JCI33295. View

Yeon C, Pegram M . Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005; 23(5):391-409. DOI: 10.1007/s10637-005-2899-8. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Rogner U, Wilke K, Steck E, Korn B, Poustka A . The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics. 1995; 29(3):725-31. DOI: 10.1006/geno.1995.9945. View

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B . A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038):1643-7. DOI: 10.1126/science.1840703. View

Rabindran S . Antitumor activity of HER-2 inhibitors. Cancer Lett. 2005; 227(1):9-23. DOI: 10.1016/j.canlet.2004.11.015. View

10.

Sugita M, Geraci M, Gao B, Powell R, Hirsch F, Johnson G . Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 2002; 62(14):3971-9. View

11.

Ross J, Fletcher J, Linette G, Stec J, Clark E, Ayers M . The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003; 8(4):307-25. DOI: 10.1634/theoncologist.8-4-307. View

12.

Busam K, Iversen K, Berwick M, Spagnoli G, Old L, Jungbluth A . Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol. 2000; 13(4):459-65. DOI: 10.1038/modpathol.3880078. View

13.

Goldhirsch A, Glick J, Gelber R, Coates A, Thurlimann B, Senn H . Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005; 16(10):1569-83. DOI: 10.1093/annonc/mdi326. View

14.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

15.

Simpson A, Caballero O, Jungbluth A, Chen Y, Old L . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8):615-25. DOI: 10.1038/nrc1669. View

16.

Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L . High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer. 2009; 125(6):1365-71. DOI: 10.1002/ijc.24503. View

17.

Zendman A, Ruiter D, van Muijen G . Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol. 2003; 194(3):272-88. DOI: 10.1002/jcp.10215. View

18.

Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L . Melanoma-associated antigen genes - an update. Cancer Lett. 2010; 302(2):85-90. DOI: 10.1016/j.canlet.2010.10.021. View

19.

Weigelt B, Reis-Filho J . Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol. 2009; 6(12):718-30. DOI: 10.1038/nrclinonc.2009.166. View

20.

Kufer P, Zippelius A, Lutterbuse R, Mecklenburg I, Enzmann T, Montag A . Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res. 2002; 62(1):251-61. View